Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01090817Phase 2Completed

An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease

Role: lead

NCT01742260Phase 1Unknown

Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials

Role: lead

NCT01589549Phase 2Unknown

Mesenchymal Stromal Cells for Acute Graft Versus Host Disease

Role: lead

NCT01795781Completed

Assays for and Reversal of New Anticoagulants

Role: lead

All 4 trials loaded